All posts by imreal

Study Shows 74% of North Americans Have “Air Quality Anxiety”—AprilAire Solutions Alleviate Concerns


News Image

AprilAire Healthy Air Professionals install the AprilAire Ventilating Dehumidifier in a new home.

AprilAire, the nationwide leader in professional-grade Healthy Air solutions for the home since 1954, experienced a significant increase in product queries and purchases since the pandemic and significantly expanded its manufacturing and distribution sites in 2021. Paired with a 2022 study that shows 74% of North Americans worry about indoor air quality (IAQ) and have “air quality anxiety,” the time is right to talk about healthy indoor air and how to get it with AprilAire’s residential solutions to improve the quality of air nationwide with air purifiers, dehumidifiers, humidifiers, air filters, and the AprilAire Healthy Air System®, which is a comprehensive, all-in-one offering. Earlier this year the company added radon testing and mitigation to its suite of healthy air products.

Air pollution is a big deal globally. Here in the states, a July 2022 study by Boston College’s Global Observatory on Planetary Health showed that pollution levels in Massachusetts were responsible for 2,780 deaths in 2019 alone. The Boston College research examines the far-reaching impact of pollution on public health in the state.

Americans spend 90% of their time inside but indoor air can be up to five times more polluted than the air outside, according [the EPA. A 2022 study commissioned by Ambius proves that people now care about indoor air. Overall, 74% of respondents felt anxious when entering indoor spaces with a perceived air quality problem, 70% believed their workspace needed air quality improvement, and 69% saw lack of investment in health and safety as an issue.

AprilAire addresses these concerns and offers homeowners indoor air quality peace of mind for the whole house no matter the season. Summer humidity is balanced with the company’s line of dehumidifiers for comfort as well as homeowner health and a house’s physical structure. Conversely, in the winter, AprilAire whole-house humidifiers make dry, winter air more comfortable and healthy. AprilAire has been providing these professional-grade, residential Healthy Air solutions since 1954 as well as air purifiers, and a complete line of air filters that can remove up to 99%* of allergy and asthma triggers, including smoke, pollen, mold, and more, and can capture 98%* of airborne viruses. The company’s signature solution, the AprilAire Healthy Air System®, is a set-it-and-forget-it system for all-in-one fresh air ventilation, air purification, humidity control, zoning, control, and radon mitigation which are all essential to maintaining proper indoor air quality no matter the weather outside.

*Contaminants removed based on air passing through the filtering system.

About AprilAire

AprilAire is on a mission to make homes healthy. We believe everyone deserves Healthy Air and envision a future with Healthy Air in every home. We value healthy living, customer inspired innovation, simplicity of design, straight talk and delivering real results as promised, and most importantly making a positive difference in the lives of our customers, families, and communities. Headquartered in Madison, Wisconsin since 1954, AprilAire has been creating and delivering Healthy Air solutions to manage air purity, humidity, fresh air supply, radon mitigation, and temperature for all types of homes, in all environments. We have an unparalleled reputation as the brand of choice among tens of thousands of professional contractors and make a Healthy Air difference in the lives of the millions of families who rely on our products every day. To learn how to turn your house into a Healthy Home with the AprilAire Healthy Air System® and learn about other solutions, visit http://www.aprilaire.com.

# # #

Share article on social media or email:

IntellectAbility’s innovative curriculum in IDD healthcare meets the needs


2022 Rick Guidotti, Positive Exposure. All rights reserved.

People with intellectual disabilities are entitled to quality medical care that goes beyond intellectual disability services. When providers misinterpret and misdiagnose symptoms, serious health issues may go untreated.

According to a recent Sentinel Event Alert from The Joint Commission, medical providers engage in diagnostic overshadowing when treating patients with existing disabilities. Providers are liable to overlook medical issues because they assume symptoms are related to the person’s intellectual/developmental disability (IDD).They may not do appropriate diagnostic testing to check for treatable conditions. Failure to diagnose and treat underlying health issues endangers people with IDD.

“People with intellectual disabilities are entitled to quality medical care that goes beyond intellectual disability services. When providers misinterpret and misdiagnose symptoms, serious health issues may go untreated,” says Dr. Craig Escudé, a physician and president of IntellectAbility. “It’s critical that any health care provider working in a clinical setting understand how to interact with people of all abilities and their caregivers. We applaud the Joint Commission for raising awareness about the need for expanded training in this area.”

Misdiagnosis or lack of diagnosis can lead to quantifiable harm. In some cases, people with IDD are prescribed psychotropic medications to treat behaviors that are simply attributed to the person’s disability rather than looking for the root cause that may be a physical condition such as a dental abscess or gastrointestinal problem. The delay in appropriate diagnosis and treatment exacerbates the physical condition while also exposing the person to unnecessary medications.

In their investigation of diagnostic overshadowing, The Joint Commission discovered that as many as one-third of U.S. physicians are not familiar with legal requirements under the Americans with Disabilities Act (ADA). Most U.S. medical schools do not provide disability healthcare competency training, leaving physicians with limited opportunities to learn best practices in working with patients who have IDD diagnoses. In response, the Joint Commission calls for improved “awareness of diagnostic overshadowing during clinical peer and quality assurance reviews and by addressing it in training and education programs.”

The Joint Commission laid out clear actions that health care providers can adopt to mitigate diagnostic overshadowing in their practices. IntellectAbility innovations are aligned with the JC’s recommendations:

Recommendation: Create an awareness of diagnostic overshadowing during clinical peer and quality assurance reviews by addressing it in training and education programs.

IntellectAbility’s Curriculum in IDD Healthcare (CIDDH) includes a section specifically designed to instruct health care professions students and practicing clinicians on how to “unlock the language of behavior.” The training emphasizes how in-depth assessment of behavioral or psychiatric symptoms can lead to diagnosis and treatment of underlying medical conditions.

Recommendation: Use listening and interviewing techniques designed to gain better patient engagement and shared decision-making.

IntellectAbility’s CIDDH provides concrete recommendations for directly and actively engaging people with IDD in their health management. CIDDH specifically includes effective communication strategies for supporting people who may not communicate using words. The training also emphasizes the key role of supporters and family members during the diagnosis and treatment process.

Recommendation: Collect and aggregate data about pre-existing conditions and disabilities and create electronic health record (EHR) prompts for clinicians.

IntellectAbility’s Health Risk Screening Tool is a well-established and trusted web-based tool that detects health destabilization and contains a wide range of data that informs the person’s health risk level. The HRST aggregates data about a person’s medications, medical conditions, and other key health-related information and is interoperable with other IT/EHR and case management systems.

When a health risk is identified, the HRST provides “service considerations” to providers. For example, the tool may suggest a gastrointestinal consultation and appropriate follow-up for a person found to be at risk for severe constipation or bowel obstruction.

The HRST also includes information about the signs a particular person might express with the onset of a known condition. The person’s history would show what behaviors they have exhibited during previous health episodes, offering providers insight into what those behaviors could mean clinically.

Recommendation: Use an intersectional framework when assessing patients in groups prone to diagnostic overshadowing to overcome cognitive biases and look beyond previous diagnoses.

IntellectAbility’s Curriculum in IDD Healthcare starts with a robust discussion on health equity for people with IDD. CIDDH addresses the need for clinicians to develop IDD Healthcare competency in order to overcome “unconscious bias” about a person’s quality of life when making treatment decisions for people with IDD. Diagnostic overshadowing can be detrimental to the quality of care and can contribute to delays in diagnosis and treatment, unnecessary or unsafe care, and inequities of care.

IntellectAbility and The Joint Commission both recognize that diagnostic overshadowing is a phenomenon that stems from a correctable cognitive bias. Appropriate awareness and training are crucial for clinicians seeking to overcome cognitive biases.

“Shifting to a person-centered model of medical care makes good sense,” says Dr. Escudé. “As The Joint Commission recognizes, when providers set aside bias and assumption, they can listen to patients more effectively and therefore treat them more effectively. At IntellectAbility, we have decades of experience teaching person-centered methods to clinicians and caregivers who work in intellectual and developmental disability services. Our programs can help medical providers acquire the skills called for in The Joint Commission Sentinel Event Alert.”

For more information about IntellectAbility, visit their website at https://www.replacingrisk.com/

About IntellectAbility

IntellectAbility provides tools and training to agencies, governmental entities, and supporters of people with intellectual and developmental disabilities (IDD) to foster early recognition and mitigation of health risks, thereby improving health and wellness. One such tool is the Health Risk Screening Tool (HRST), of which they are the sole developer, producer, and distributor. The web-based HRST is the most widely used and validated health risk screening instrument for people with intellectual and developmental disabilities.

The Curriculum in IDD Healthcare (CIDDH) was created by Dr. Craig Escude, a physician specializing in developmental medicine, to serve as a comprehensive IDD training curriculum in six online modules for physicians, nurse practitioners, nurses, and physician assistants. The curriculum focuses on pertinent, practical information that can be put to use immediately in practice to increase provider IDD healthcare competency and improve outcomes for people with IDD. Upon completion, 5 CMEs and/or 6 Nursing CEU Credit Hours are awarded.

IntellectAbility also provides numerous health-related and person-centered service trainings for supporters of people with IDD. With an unrelenting focus, IntellectAbility works to fulfill its mission of improving health and quality of life for people with intellectual and developmental disabilities and other at-risk populations. For more information, visit http://www.ReplacingRisk.com

1.    Gleason, Ross, Fossi, Blonsky, Tobias, Stephens.The Devastating Impact of Covid-19 on Individuals with Intellectual Disabilities in the United States. NEJM Innovations in Care Delivery. March 2021.

2.    Iezzoni LI, et al. U.S. physicians’ knowledge about the Americans with Disability Act and accommodation of patients with disability. Health Affairs, Jan. 2022.

3.    National Council on Disability. Policy Framework. Health Equity Framework for People with Disabilities. Feb. 2022.

4.    The Joint Commission. Diagnostic overshadowing among groups experiencing health disparities. June 2022.

Curio Wellness Launches Two Product Lines Focused on Gut Health and Active Lifestyles


News Image

“GI and Move are two prime examples of how our clinical-based approach is helping to reimagine the way medicinal cannabis is delivered to patients who need it most.” – Sandra Hutson, Vice President, Innovation at Curio Wellness

Curio Wellness, a cGMP-certified, vertically integrated medical cannabis company and market leading innovator of health and wellness products derived from cannabis, has announced the launch of two scientifically-developed product lines: GI by Curio and Move by Curio.

GI by Curio is a plant-powered collection designed to improve quality of life, offer accessible options for patients facing gut discomfort or symptoms such as bloating and cramps, and to help improve the body’s gut health. Leveraging advanced science and Curio’s proprietary patent pending pulse technology, this is the one of the first gut-focused, cannabis-derived therapeutic lines by a cannabis brand nationwide.

The GI by Curio collection includes:

  • Soothe Vape and Tincture: For patients experiencing nausea or upset stomach, quick delivery is essential. The vape and tincture allow for a faster onset since the cannabinoids bypass the digestive system.
  • Stimulate Chew: The medicated chew was created to help patients who struggle with reduced or no appetite.
  • Comfort Tablet: Specifically formulated to address chronic GI issues, the patent pending GI: Comfort tablet doses CBG and low THC in multiple pulses released at different intervals.

Move by Curio is the company’s first line of topical products designed to offer targeted relief for those with active lifestyles. The collection includes three treatments — a topical balm, transdermal balm and transdermal gel — that are unscented and non-greasy for optimal and targeted application.

“Curio’s commitment to continuous product research and innovation stems from our mission to develop targeted therapeutics that are safe, effective and reliable for patients seeking alternative, plant-based relief,” said Sandra Hutson, Vice President, Innovation at Curio Wellness. “GI and Move are two prime examples of how our clinical-based approach is helping to reimagine the way medicinal cannabis is delivered to patients who need it most.”

GI and Move join the company’s portfolio of innovative cannabis products that help address and alleviate symptoms for a wide array of medical conditions – from pain management to insomnia. Today marks the statewide release of the GI Soothe Vape, Stimulate Chew and Comfort Tablet. The Soothe Tincture will join the GI by Curio collection in September. Move by Curio will be available at dispensaries across Maryland starting August 8.

Curio Wellness was the first cannabis producer in Maryland awarded cGMP certification, the same quality standard set by the FDA for the world’s leading pharmaceutical companies.

###

About Curio Wellness

Founded in 2014 in Baltimore, Maryland, Curio Wellness is a cGMP certified, vertically integrated medical cannabis company and trusted healthcare partner. Recognized as the leading wellness brand in cannabis by BDS Analytics, Curio is committed to serving patients with targeted, effective, and reliable cannabis-based medicine. For more information visit https://curiowellness.com.

Share article on social media or email:

Shai Efrati, MD, the World’s Leading Research Scientist and Innovator in Hyperbaric Medicine, to Keynote at the Global Wellness Summit


News Image

Our new studies demonstrate something for the first time and it’s the ‘holy grail’ of wellness: We can actually reverse the biology of aging and take cellular and brain function back in time.

The Global Wellness Summit (GWS), the most prestigious conference on the $4.4 trillion business of wellness, announced today that Shai Efrati, MD, the world’s foremost research scientist on hyperbaric oxygen therapy, will keynote at the conference being held at the Hilton Tel Aviv from October 31 to November 3. Efrati is a professor at Sackler School of Medicine and the Sagol School of Neuroscience at Tel Aviv University and director of the Sagol Center for Hyperbaric Medicine and Research at Shamir Medical Center–the largest hyperbaric center in the world, treating over 350 patients a day.

Efrati’s lab has created a unique approach for hyperbaric oxygen therapy (HBOT) which consists of immersing people in a high-pressure, high-oxygen environment and then carefully regulating oxygen and pressure levels. This technique, which is called the hyperoxic-hypoxic paradox (HHP), “tricks” the body into entering a regenerative state which unleashes a cascade of biological changes. These include the proliferation of stem cells, the generation of new blood vessels, and the repair of brain cells and tissue.

Eye-opening evidence:

Over the last decade, Efrati’s research team has authored dozens of high-quality clinical studies that show how this specific HBOT therapy revolving around the hyperoxic-hypoxic paradox has eye-opening impact on so many conditions. It can significantly boost brain function in stroke and traumatic brain injury patients, heal the wounds in the brain caused by PTSD, improve sexual function, and roll back the process of skin aging. This month, their randomized controlled trial found that the therapy incited brain healing and improved myriad symptoms in long Covid sufferers, an area where solutions have been elusive.

But it’s his recent research on healthy individuals that has such extraordinary implications for the wellness world. The therapy was recently shown to significantly improve (not just slow the loss of) cognitive function in healthy, older adults by generating new neurons and blood vessels in the brain–the first study to demonstrate that a brain can be made “younger.” Another recent study revealed that the treatment reversed two major processes associated with aging and its illnesses: the shortening of telomeres (the protective caps at the ends of every chromosome) and the accumulation of old, malfunctioning cells in the body. Participants’ telomeres were lengthened up to 38% while senescent cells saw a decrease of up to 37%.

“Our new studies demonstrate something for the first time and it’s the ‘holy grail’ of wellness: We can actually reverse the biology of aging and take cellular and brain function back in time. It’s analogous to the first time that man landed on the moon. After that first landing, everyone wanted to travel there, but even faster and more effectively. So, we’ll see young scientists rush to study aging and huge investment in this area,” said Efrati. “Aging isn’t a bad thing; it’s the functional decline that is. As the wellness world knows well, many more people seek solutions that can make them fully potent and active every single year of their life. The future is high-performance aging, and I’m excited to share my vision of that future–and the rising place of hyperbaric oxygen therapy in the medical-wellness world–with the leaders that will gather at the Summit.”

Caution: This isn’t the “hyperbaric oxygen treatment” at your corner spa:

Hyperbaric oxygen treatments are spawning at spas and wellness centers and with at-home products. But, as Efrati cautions, it’s not even the same approach: these offerings simply involve putting people in a sack, or pod, full of minimally pressurized, oxygenated air, when that’s not what makes HBOT effective. “The game-changing component is the hyperoxic-hypoxic paradox: the precise protocols we’ve optimized for oxygen and pressure levels, fluctuations, and durations that spark the regenerative process in the body, said Efrati. “This evidence-based therapy has to be performed in a medical facility by a trained physician. All these oxygen spas and pods can be dangerous: they miss the quality assurance of the air pump being inside, and they pose threats of oxygen toxicity and other health issues. They’re also not effective. The future is clearing up much confusion in the marketplace about what evidence-based hyperbaric oxygen therapy actually entails and achieves.”

Aviv Clinics: Rolling out this evidence-based treatment globally:

To make a more powerful global impact and to “walk faster,” Efrati co-founded AVIV Scientific, a research organization and network of global medical-wellness clinics focused on innovative applications of hyperbaric medicine using the HHP protocols, that can increase cognitive and physical performance in healthy aging adults. Clinics are open in Tel Aviv, at The Villages in central Florida, and most recently in Dubai–and are expected to come to New York and the UK soon. Aviv plans 50 clinics around the world within the next decade. Each clinic combines HBOT with personalized medicine, cognitive and fitness training, and nutrition coaching. Thanks to an exclusive partnership with the world’s largest hyperbaric research facility, the Sagol Center at Shamir Medical Center, each patient’s data and samples are sent to the center’s large research lab, where blood, DNA, telomeres, MRI results, etc. are analyzed. Since Sagol Center is doing so much research, positive findings can immediately be implemented at the clinics. For instance, with their new trial indicating that HBOT can help with long Covid damage to the brain, new programs were quickly rolled out.

“Every year we aim to bring the brightest stars in health and wellness to the stage, and Dr. Efrati is exactly the kind of innovator we seek: a dynamic thinker whose work will really shake up our future, whose solutions are grounded in evidence, and who understands that new connections between medicine and wellness lie ahead,” said Susie Ellis, GWS chair and CEO. “It’s an incredible opportunity for delegates to be immersed in his research on the future of aging at such an early, pivotal moment. What he’s doing is game-changing.”

Registration for the 2022 Summit is now open.

About the Global Wellness Summit — The Global Wellness Summit is the premier organization that brings together leaders and visionaries to positively shape the future of the $4.4 trillion global wellness economy. Its future-focused conference is held at a different global location each year and has traveled to the United States, Switzerland, Turkey, Bali, India, Morocco, Mexico, Austria, Italy and Singapore. GWS also hosts other virtual and in-person gatherings, including Wellness Master Classes, Wellness Sector Spotlights, Investor “Reverse Pitch” events and Global Wellness Symposiums. The organization’s annual Global Wellness Trends Report offers expert-based predictions on the future of wellness. The 2022 Summit will be held in Tel Aviv, Israel from October 31 to November 3.

Share article on social media or email:

Dr. Sharmila Dorbala Will Present Keynote Lecture at ASNC2022


Sharmila Dorbala, MD, MPH, MASNC

Sharmila Dorbala, MD, MPH, MASNC

“Molecular imaging is the key to understanding the precise pathophysiology of cardiac amyloidosis and various other diseases. We will be able to use that knowledge to develop targeted therapies and also prevent organ dysfunction.” Dr. Sharmila Dorbala

Cardiac imaging specialist and cardiac amyloidosis researcher Sharmila Dorbala, MD, MPH, MASNC, will present the Mario Verani Memorial Lecture at the American Society of Nuclear Cardiology (ASNC) 2022 Annual Scientific Session and Exhibition. Her lecture, titled “Molecular Imaging of Cardiac Amyloidosis: From Unraveling Pathophysiology to Transforming Patient Care,” will examine how the recent paradigm shift in the diagnosis and treatment of transthyretin (TTR) cardiac amyloidosis has yielded lessons that may unlock the potential to prevent heart failure from amyloid as well as transform the care of patients with other diseases.

“Molecular imaging is the key to understanding the precise pathophysiology of cardiac amyloidosis and various other diseases,” Dr. Dorbala says. “We will be able to use that knowledge to develop targeted therapies and also prevent organ dysfunction.”

Dr. Dorbala is the director of nuclear cardiology at Brigham and Women’s Hospital and a professor of radiology at Harvard Medical School. She is a clinical expert in advanced cardiac SPECT and PET imaging whose research is focused on the molecular imaging of cardiac amyloidosis. Dr. Dorbala served as ASNC’s president in 2020 and is the first author of the most recent SPECT imaging guidelines as well as the two-part ASNC/Multisocietal Expert Consensus Recommendations for Multimodality Imaging in Cardiac Amyloidosis: Evidence Base and Standardized Methods of Imaging and Diagnostic Criteria and Appropriate Utilization.

TTR cardiac amyloidosis develops when a normally occurring protein in the blood begins misfolding and accumulating in the heart muscle. Over time, this accumulation can weaken the heart, often leading to heart failure. Until recently, cardiac amyloidosis was believed to be rare. Molecular-imaging-based research now has shown that TTR cardiac amyloidosis is much more prevalent than previously believed and that the condition can be accurately diagnosed with a noninvasive nuclear imaging test. The imaging test results can be used to guide therapy toward medications that stabilize or even halt the protein deposits in the heart and other organs.

“With cardiac amyloidosis, many of the advances came from luck and timing. Imaging helped us understand the pathophysiology of cardiac amyloidosis at exactly the right time – just as treatments were coming to fruition,” Dr. Dorbala says. “Let’s not wait for more serendipity. We can use molecular imaging with intent to unravel the pathophysiology of disease and to develop new imaging agents and therapeutic agents based on that pathophysiology. This is the formula for transforming patient care in the future.”

Appropriately, the theme of ASNC2022 is “Bold Approaches to Transforming Patient Care.” The conference will convene Sept. 8-11 in Orlando, Florida. Dr. Dorbala will present the Mario Verani Memorial Lecture on Sept. 9 during the Opening Plenary Session.

To register to attend ASNC2022 educational sessions as a member of the press or to arrange interviews with ASNC2022 speakers or other experts, contact Jennifer Taylor Howell at info@asnc.org.

###

About the American Society of Nuclear Cardiology

For over 25 years, the American Society of Nuclear Cardiology and its more than 4,500 members have been improving cardiovascular outcomes through image-guided patient management. As the only society dedicated solely to the field of nuclear cardiology, ASNC establishes standards for excellence in cardiovascular imaging through the development of clinical guidelines, professional medical education, advocacy and research development. ASNC provides peer-reviewed original articles through its official publication Journal of Nuclear Cardiology and operates the nation’s first noninvasive cardiac imaging registry, ImageGuide Registry®, to benchmark quality and improve patient care. For more information, visit http://www.asnc.org.

Share article on social media or email:

Deep Bio’s AI Support for Cancer Diagnosis has been Designated as an Innovative Product by the Korean Public Procurement Service


It represents an official government recognition of the innovation of our state-of-the-art technology. Through this, potential clients at national- and public institutions can better access Deep Bio’s groundbreaking software for purchase

Deep Bio, a pioneer in medical AI for digital pathology and cancer diagnostics software, announced that its AI solution for grading the severity of prostate cancer, DeepDx®-Prostate Pro, has been officially designated as an ‘Innovative Product (Fast Track II)’ by the Korean Public Procurement Service (PPS) in the bio-health sector, a public recognition of product excellence and innovation.

‘Innovative Product Designation Program’ is a government program that aims to foster the development of innovative technologies and is operated by the Korean PPS, providing public access to breakthrough technologies. To select Innovative Products, a committee made up of the Korea PPS and experts in each field, such as bio-health, future automobiles, carbon neutrality, evaluate each registrant based on several criteria including public value and innovation. As a result, Deep Bio can now execute a purchase agreement with the PPS, and the product can be registered in the Public Procurement Market.

With the registration of DeepDx®-Prostate Pro in the Public Procurement Market through this designation, the software as a medical device is now available to more than 300K national- and public institutions for purchase. With this opportunity, Deep Bio is expected to lay the groundwork for market expansion as well as demonstrate the clinical utility of its software.

“We are delighted that the Korean PPS designated DeepDx®-Prostate Pro as an Innovative Product. It represents an official government recognition of the innovation of our state-of-the-art technology. Through this, potential clients at national- and public institutions can better access Deep Bio’s groundbreaking software for purchase”, said Sun-Woo Kim, CEO of Deep Bio. “We also hope that this will be a great opportunity to confirm the robust performance and value of our software when implemented into real clinical workflows,” added he.

DeepDx®-Prostate Pro is a deep learning-based medical software that assists the histopathological diagnosis of prostate cancer by analyzing the Whole Slide Image (WSI) of the prostate needle biopsies. It automatically classifies the severity of prostate cancer based on the Gleason grading system, which is the most widely-used method for evaluating the degree of differentiation of prostate cancer tissues. The software has received Korea MFDS (Ministry of Food and Drug Safety) approval as a Class III medical device in November 2021. In a clinical validation study, the analysis by the software showed high concordance with the reference standard established by experienced board-certified pathologists. In addition, the software improved workflows by significantly reducing time spent by pathologists on analysis of each slide. The study results were published in Modern Pathology.

Focusing not only on AI diagnostics but also on R&D, Deep Bio has been presenting its novel research results in prestigious science and technology journals including the Cancers Journal, npj Digital Medicine, as well as in various international conferences and events. The company also continues to build its global presence through overseas digital pathology solution providers in the US, Europe, and India, as well as conducting research cooperation with Stanford Medical School, Harvard Dana-Farber Cancer Institute, and other top research institutions in the US.

About Deep Bio

Deep Bio Inc. is an AI healthcare company with in-house expertise in deep learning and cancer pathology. As the country’s first to obtain Korea’s MFDS (Ministry of Food and Drug Safety) approval of an AI-based cancer diagnostic support solution, Deep Bio’s vision is to radically improve efficiency and accuracy of pathologic cancer diagnosis and prognosis, by equipping pathologists with deep learning-based IVD SaMDs (In Vitro Diagnostics Software as a Medical Device), for optimal cancer treatment decisions. Deep Bio is also actively engaged in the research space and maintains ongoing collaborations with top US medical centers. To learn more, visit http://www.deepbio.co.kr.

DeepDx® Prostate is a clinically-validated AI for prostate core needle biopsy tissue image analysis. Whole-slide images (WSIs) of H&E-stained biopsy tissue specimens are analyzed for prostate cancer, Gleason scores, and grade groups. Extensively tested at US CLIA labs (> 700k cores between 2019 and 2021), DeepDx® Prostate can alleviate the shortage of pathologists and the resultant increase in workload, while reducing diagnostic subjectivity and variability.” To learn more, visit http://www.deepbio.co.kr.

Share article on social media or email:

Gene Therapies for Hemophilia Treatment Will Face Strong Market Headwinds, Research Suggests


The latest results from APLUSA’s annual syndicated market surveillance tracker in hemophilia A and B, HEMOPHILIAsyndiTrack™, published in June, show that while unaided awareness of gene therapy for the treatment of both hemophilia A and B is high among physicians – 55% vs. 32% for antithrombin RNAi (RNAi) therapy and 30% for anti-tissue factor pathway inhibitor (TFPI) therapy – the unaided awareness of the specific gene therapies is very low (<5%), while at the same time, 29% of physicians mention Fitusiran (RNAi therapy) and 21% mention Concizumab (TFPI). Despite the generally high awareness of gene therapies, physicians are nearly equally likely to consider prescribing gene therapy within the first year after launch (56%) as they are for RNAi (51%) and TFPI (49%) therapies. Further, the prescribing decision is highly likely to be patient-directed, with physicians basing treatment on the patient’s satisfaction with current therapy.

According to HEMOPHILIAsyndiTrack™ study findings, which captures real-world patient chart data as provided by treating physicians, Hemlibra has been growing share steadily since 2019. At that time, Hemlibra was prescribed in 2% of the study’s patients with Hemophilia A – the most prevalent form of Hemophilia – and share has since grown to 22% in the most recent wave of the study. When asked about future intent, 19% of Hemophilia A treaters anticipate that they will increase their use of Hemlibra significantly, and 41% said they would increase use slightly.

The future success of gene therapies among Hemophilia A patients is further clouded by the heavy overlap in target patients, as Hemlibra and gene therapies both target younger, more physically active and severe patients. Additionally, Hemlibra patients have reported a generally positive experience on the product. APLUSA’s research shows that patients taking Hemlibra experience the lowest number annually of bleeds that require additional on-demand injections – even though Hemlibra patients are the most physically active and severe cases of Hemophilia A. This protection, combined with the reduced burden of treatment in terms of frequency and mode of injections, results in overall improvements in patient quality of life. In this context the anticipated benefits of gene therapy are not that compelling, especially given the questions related to long term side effects and efficacy of gene therapy.

“Something about gene therapy just makes me uneasy,” says one Hemophilia A patient diagnosed with severe disease, “even if I have to go through a year of immune suppressants and side effects and it does work, I’d still rather keep doing what I’m doing. There are too many unknowns for me to feel comfortable with it.”

Additional ‘voice of the patient’ social media studies conducted by APLUSA uncovered additional hesitancy and doubt among both Hemophilia A and B patients specifically regarding gene therapies. Patients with severe disease expressed concerns about the number of unknowns with gene therapies; belief that gene therapy would not ultimately result in much improvement in their quality of life; and problems with the adeno-associated virus (AAV) vector-based gene therapies – where people previously exposed to adenoviruses often had an immune mediated response resulting in anti-adenovirus antibodies, and therefore may not be good candidates for gene therapy.

According to Dr. Karen Higginbottom, APLUSA’s resident hematology expert, “These market factors – particularly the continued growth and potential entrenchment of Hemlibra – will create an uphill battle for gene therapies in the Hemophilia market.”

About APLUSA

APLUSA (with US affiliate APLUSA Bell Falla) is one of the world’s leading independent market research companies dedicated to healthcare. Thanks to the excellence and commitment of our teams, our challenge for globalization has been well and truly met. More than half of our turnover is generated overseas, two-thirds of our services are international (conducted in 75 countries), and our teams are a true reflection of our business: multi-nationals. We are now, globally, among the Top 10 Global Healthcare Market Research Companies, and the Top 3 Independent Players. The acquisition of IFOP and Sociovision and their inclusion into the APLUSA-IFOP group have increased our capabilities to develop innovative solutions based on advanced techniques used outside the health industry.

For more information on APLUSA, please visit us at https://www.aplusaresearch.com.

Share article on social media or email:

SPRINTEX Trainingsgaerete GmbH launches the new Callis PRO slat-belt treadmill line


“We are proud to introduce the next generation of our leading slat-belt treadmills with new advanced performance, safety and convenience features.” said Waldemar Rauch, Managing Director of Sprintex Treadmills.

Sprintex Trainingsgeraete GmbH manufactures high performance slat-belt treadmills since 1994 and has gained a reputation for top quality and performance treadmills for medical rehabilitation, motion analysis and sports/wellness applications.

Sprintex Trainingsgeraete GmbH, a leading provider and manufacturer for slat-belt treadmills announces the introduction of the next generation of Callis PRO treadmills for use in medical rehabilitation, motion analysis and high performance sports/wellness applications.

Callis treadmills are slat-belt treadmills that offer a unique natural gait and running experience based on an air-cushioned slat design that absorbs up to 90% of the impact while walking and running. A frictionless belt design ensures no slippage like in conventional treadmills and at the same time a low energy consumption. An enhanced speed control across all models provides stable low speed applications for impaired patients as well as stable high speed applications for athletes.

Now the Callis PRO generation will offer a new intuitive user interface with enhanced features such as user specific programs, goal oriented training and recording of the training exercise. A wealth of new options such as wider belts, high speed up to 18.5mph or 30 km/h, higher incline up to 25%, remote control, a safety option for home use and a new innovative biofeedback functionality complement the modular approach of today’s treadmill generation and make the Callis PRO the leading high performance slat-belt treadmill line for gait rehabilitation, motion analysis as well as sports and wellness activities.

About the Company:

Sprintex was established in 1994 with a mission to develop high quality and performance slat-belt treadmills that effectively support patient rehabilitation training to regain their walking ability, advanced motion analysis applications with professional motion analysis systems such as MotionMetrix or professional athletes and hobby runners in their workouts for sports and wellness activities. “Specifically, we translate the technological progress and clinical and other professional experience gained in the past 28 years into robust high performance treadmills to serve our clients in the medical, motion analysis and sports fields.” said Waldemar Rauch, Managing Director of Sprintex Treadmills.

If you have any questions regarding information in these press releases please contact the company listed in the press release.

Share article on social media or email:

United Nations Association-USA Awards Bay Area High School Student Community Service Impact National Recognition


Monta Vista High School announced that Urmi Sumant is being recognized by the United Nations Association of the USA (UNA-USA) and InnerView in the 5th Annual National Community Service Impact Awards. Open to all U.S. high school students, the program connects student community service activities, skill development, and personal commitment to the Sustainable Development Goals (SDGs) to transform our world.

Urmi Sumant is a teacher, entrepreneur, volunteer, and leader who seeks to positively impact the world.. She takes a deep dive into any field she is passionate about as demonstrated by her ability to speak, read, and write in five languages; extensive violin performance experience of 10 years; and leadership in Earnit, a non-profit organization focused on health and well-being. As a winner of the UN Ambassador Award for 350+ hours of community service, her dedication to the community is unparalleled and inspiring.

“Youth efforts and voices are essential to achieve the SDGs, said Rachel Bowen Pittman, Executive Director of United Nations Association-USA. “These awards allow us to share our appreciation for youth leaders who have invested talent and effort in the causes they care about. With a decade remaining to deliver on the SDGs, we are thrilled that these students will be entering the workforce with meaningful community engagement skills and socially aware experiences.”

Sumant’s comprehensive experience with leadership and community service led to her national recognition. As a teacher at JET USA, a position usually reserved for adults, she inspires young first-generation Americans to practice traditional Indian values to give them a strong foundation in life management. She has even given a recent TEDx talk: Make Yoga and Meditation part of you to navigate your life. As the founder of Earnit, a nonprofit organization to support small businesses while incentivizing exercise, she serves her community by increasing physical fitness levels. As a leader, she inspires those around her to act.

Monta Vista High School principal Ben Clausnitzer said, “Urmi delivered the most impact for SDG’s Good Health and Well-Being award. She is an excellent Monta Vista student who has demonstrated exceptional commitment to the school community and beyond. I am confident that her recognition as a UN Ambassador will inspire others to make similarly meaningful contributions to society.”

According to Kristine Sturgeon, CEO of InnerView Technologies “We are honored to work with the national service ecosystem and local communities to amplify and recognize the meaningful work of student volunteers who are creating a better world for all. Purpose-driven students continue to generously invest time and talent in causes they care about. We believe the dynamics of the last few years have significantly influenced the personal understanding of the connectedness between all people and local and global challenges; this has manifested into an increase of youth volunteer time addressing local needs and leading meaningful projects.”

According to Sumant, “Serving my community is a foundational passion for me. Specifically, helping the next generation adapt to the ever-changing environment and teaching them how to effectively navigate these changes is really important to me. Much of my community work is focused on achieving physical and mental wellness.”

When asked about advice she has for students just starting their community service journey, Sumant said, “Follow your passions and dive deep into them. Many people do community service just for the sake of it. But that’s a lot of valuable time which could be better spent doing something a lot more impactful and personally fulfilling.”

About United Nations Association – USA

The United Nations Association of the USA (UNA-USA) is a grassroots movement of Americans who support the vital work of the United Nations in U.S. communities, colleges, and U.S. Congress. With over 20,000 members — 60% under the age of 26 — and more than 200 chapters across the country, UNA-USA members are united in their commitment to global engagement and their belief that individuals can play a part in advancing the UN’s mission and achieving the Sustainable Development Goals. Learn more: https://unausa.org/

About InnerView Technologies

InnerView is the leading youth social responsibility platform to help students, groups, and schools highlight community service impact, passion for causes, skill development, and connect local efforts to the UN Sustainable Development Goals. All college and high school-aged students are welcome to join tens of thousands of 14- to 24-year-olds who have discovered ways to get involved and develop dynamic visual service resumes through my InnerView Technologies is a social impact organization working with students, groups, schools, nonprofits, and committed & compassionate institutions. Learn more at https://InnerView.org

Contact Information:

Ben Clausnitzer, Monta Vista High

408-366-7601

ben_clausnitzer@fuhsd.org

Elizabeth Lemons, UNA – USA

202-496-6384

elemons@unfoundation.org

Brianna Fedak, InnerView Technologies

440-520-0823

Brianna@InnerView.org

Share article on social media or email:

Boston researcher Ramachandran selected to be inaugural dean of The University of Texas School of Public Health San Antonio


“Launching the new School of Public Health in San Antonio is a transformative opportunity…” — Vasan Ramachandran, MD

Vasan Ramachandran, MD, a distinguished public health researcher at Boston University and principal investigator of the Framingham Heart Study, has been named founding dean of The University of Texas School of Public Health San Antonio. The new school is a strategic collaboration of The University of Texas Health Science Center at San Antonio (UT Health San Antonio) and The University of Texas at San Antonio (UTSA) and is one of three schools of public health in The University of Texas System.

William L. Henrich, MD, MACP, president of UT Health San Antonio, and Taylor Eighmy, PhD, president of UTSA, jointly announced Ramachandran’s appointment, which is effective Sept. 1.

An internationally known and highly respected physician-scientist and clinical epidemiologist, Ramachandran’s research has focused on heart failure, blood pressure and cardiac remodeling. “Vasan is the ideal person to lead and build our city’s new School of Public Health,” Henrich said. “His leadership of multiple studies gathering data on biological and lifestyle risk factors, his impressive track record of National Institutes of Health funding, his mentorship of diverse students, and his experience directing the first public health school in India all attest to this.”

In addition to Ramachandran’s extensive and relevant experience, he is “a thoughtful, collaborative and authentic leader who has the heart of a public servant,” Henrich said.

Establishment of the School of Public Health and recruitment of its dean introduces a new era for UTSA’s and UT Health San Antonio’s shared mission to serve the public good, Eighmy said. “We seek to improve public health in close partnership with the city of San Antonio, Bexar County, our research and development partners, and the health care community. This new school allows us to meet critical public health workforce needs and is a major boost to both institutions’ positive momentum and commitment to being a center of excellence in public health education, service and research,” he said.

“The new joint school of public health by UT Health Science Center San Antonio and UTSA will be a tremendous resource for San Antonio and South Texas, and the appointment of an outstanding inaugural dean demonstrates the power of this collaboration,” UT System Chancellor James B. Milliken said. “The Board of Regents and I are looking forward to Dr. Ramachandran’s leadership and to the success of this important new school.”

Pandemic exacerbated issues

“Launching the new School of Public Health in San Antonio is a transformative opportunity of a lifetime,” Ramachandran said in a phone interview this week. “We are starting the School of Public Health at a very critical time in the history of the country, the state, the city and the region. We are still in the throes of a pandemic, two and a half years plus, and this crisis has exposed how challenging it is to deal with major public health challenges on the scale of the COVID-19 pandemic.”

Much of the frontline battle of the pandemic is fought by public health workers, and yet there is a gap in infrastructure related to the training of the public health workforce, Ramachandran said. “Meanwhile, the pandemic continues in the context of the burden of chronic disease, which is very high in this region,” he said.

The pandemic has also revealed “a social patterning of disease,” Ramachandran said. Demographic characteristics of people who have been worst hit are frontline workers, people of color, people who lack health insurance, mothers of young children and other vulnerable populations.

“Throughout the course of the pandemic, we have navigated, feeling our way, because it’s been very dynamic,” Ramachandran said. “And we have tried to carry the public along with us, not always successfully.”

UT Health San Antonio and UTSA each offer complementary programs and synergy to the new School of Public Health, said Jennifer Potter, PhD, vice president for research at UT Health San Antonio. For example, infectious diseases, cancer, epidemiology and many other areas of study are strengths of UT Health. UTSA contributes data sciences, kinesiology, demography and other diverse areas. Potter co-chaired the Search Advisory Committee with Heather Shipley, PhD, senior vice provost of academic affairs and dean of University College at UTSA, along with seventeen colleagues from UT Health San Antonio, UTSA and the San Antonio community.

Decades of experience

Ramachandran has served on the faculty of the Boston University School of Medicine and School of Public Health for more than a quarter-century and as principal investigator of the Framingham Heart Study since 2014. The Framingham study is a population-based, observational cohort study initiated by the U.S. Public Health Service in 1948 and subsequently funded by the National Heart, Lung, and Blood Institute to prospectively investigate the epidemiology and risk factors for cardiovascular disease. It has grown into an ongoing, longitudinal study gathering prospective data on a wide variety of biological and lifestyle risk factors and on cardiovascular, neurological and other types of disease outcomes across three generations of participants and its accompanying Omni cohorts of non-white individuals.

Ramachandran also has served since 2019 as one of the principal investigators for the Risk Underlying Rural Areas Longitudinal Study (RURAL) aimed at addressing critical gaps in the knowledge of heart and lung disorders in rural counties in the southeastern U.S. This study is of 4,600 individuals ages 25-64 from 10 rural counties in Southern Appalachia and the Mississippi Delta.

With a current active annual research grant portfolio of nearly $20 million and as a recipient of more than $100 million from the National Institutes of Health over the last 20 years, Dr. Ramachandran is a prolific and collaborative investigator. He has more than 1,060 publications to his name, including many in prominent journals such as The New England Journal of Medicine, the Journal of the American College of Cardiology, the Journal of the American Medical Association and Circulation.

Region’s unique needs

San Antonio is a majority-minority city that, with its large and growing Hispanic population, reflects the demographic future of the nation. Many areas of the city and South Texas region are identified as Health Professional Shortage Areas (HPSAs) by the U.S. Health Resources and Services Administration.

Unique health challenges include infectious diseases, diabetes, maternal and child health, mental health and substance use disorders, health care disparities, cancer and injury prevention. The new school’s faculty will propose innovative public health solutions to these problems.

Additionally, the COVID-19 pandemic produced a strong demand and need for public health education surrounding vaccination, masking, social distancing and handwashing. The School of Public Health will enable local residents to train for public health careers to meet ever-emerging health challenges.

The University of Texas System Board of Regents recognized that the region’s persistent disparities in key health outcomes require a public health approach. In November 2021, the Regents voted to authorize UT Health San Antonio and UTSA to develop a new public health school.

A student census of almost 400 is planned within the first five years, with a Master of Public Health degree offered beginning in 2024 and a Doctor of Public Health degree program to be developed.

Total startup costs for the School of Public Health are budgeted at approximately $40 million, including existing building renovations, program development and Ramachandran’s recruitment as dean. In June, Bexar County allocated $10 million to support the school’s development.

The public is invited to tour The University of Texas School of Public Health San Antonio website.

The University of Texas Health Science Center at San Antonio (UT Health San Antonio) is a primary driver for San Antonio’s $42.4 billion health care and biosciences sector, the city’s largest economic generator. As the largest research university in South Texas, with an annual research portfolio of approximately $350 million, UT Health San Antonio drives substantial economic impact through its five professional schools, a diverse workforce of 7,200, an annual operating budget of more than $1 billion and a clinical practice that provides more than 2 million patient visits each year. Furthermore, UT Health San Antonio plans to add more than 1,500 higher-wage jobs over the next five years to serve San Antonio, Bexar County and South Texas. To learn about the many ways “We make lives better®,” visit https://www.uthscsa.edu.

Stay connected with The University of Texas Health Science Center at San Antonio on Facebook, Twitter, LinkedIn, Instagram and YouTube.

The University of Texas at San Antonio is a Tier One research university and a Hispanic Serving Institution specializing in cyber, health, fundamental futures, and social-economic transformation. With more than 34,000 students, it is the largest university in the San Antonio metropolitan region. UTSA advances knowledge through research and discovery, teaching and learning, community engagement and public service. The university embraces multicultural traditions and serves as a center for intellectual and creative resources as well as a catalyst for socioeconomic development and the commercialization of intellectual property—for Texas, the nation and the world. Learn more online, on UTSA Today or on Twitter, Instagram, Facebook, YouTube or LinkedIn.